Posted BY: Bill | NwoReport

A recently uncovered “Confidential Pfizer Report” obtained through a Freedom of Information Act (FOIA) request from 2021 has raised serious concerns about Pfizer’s knowledge of the risks associated with its mRNA COVID-19 vaccine. The report suggests that Pfizer has been aware of the vaccine’s potential dangers since February 2021.

Within just two months of its release in December 2020, the mRNA vaccine was linked to over 1,200 reported deaths and tens of thousands of adverse events, including 23 cases of spontaneous abortions and more than 2,000 reports of cardiac disorders. Despite receiving these alarming reports, Pfizer did not withdraw the vaccine, and it continued to be administered worldwide.

This revelation has led to accusations that Pfizer may have committed “manslaughter” by failing to take immediate action. However, given that the vaccine distribution continued, it now raises even graver concerns of mass genocide due to potential criminal intent. Over 60% of the world’s population has received the COVID-19 vaccine.

Trending: Corporate Dominance Grows: Ranchers’ Autonomy in Food Supply Wanes

Pfizer’s role is further complicated as it is responsible for managing safety data on behalf of its partner, BioNTech. The pharmacovigilance agreement holds both companies accountable for any safety issues.

In the early months of Operation Warp Speed in the United States, there were over 42,000 case reports, with the majority coming from the United States and the United Kingdom. This official data, outlined in a Pfizer report, provides concrete evidence for potential legal action against not only Pfizer and BioNTech but also government agencies like the FDA and CDC, the WHO, and the mass media.

The “Confidential Pfizer Report” has exposed troubling information about the Pfizer mRNA COVID-19 vaccine’s safety record and the company’s awareness of potential risks. What started as accusations of “manslaughter” for not withdrawing the vaccine has escalated to concerns of mass genocide due to ongoing distribution. With substantial evidence now available, legal actions against pharmaceutical companies and government agencies are being considered, raising questions about accountability and transparency in the context of the COVID-19 pandemic.